Researchers from Helmholtz Munich and Ludwig-Maximilians-Universität (LMU) have identified a mechanism that may explain the neurological symptoms of long COVID. The study shows that the SARS-CoV-2 ...
The drug showed promising results in an international study involving nearly 2,400 participants, and the U.S. Food and Drug ...
Background Although health problems may persist beyond 4 weeks after SARS-CoV-2 infection, evidence on long-term ophthalmic ...
New study reveals how lingering spike protein in the brain's borders could explain long-term COVID-19 neurological symptoms and highlight vaccines' protective role. Study: Persistence of spike protein ...
Following a consultation with its emergency task force, the European Medicines Agency (EMA) has backed a drug for adult patients with acute respiratory distress syndrome (ARDS) induced by the SARS‑CoV ...
Ensitrelvir represents a significant advancement in the treatment of COVID-19, setting the stage for enhanced defenses ...
Ensitrelvir is a SARS-CoV-2 main protease inhibitor created through joint research between Hokkaido University and Shionogi. SARS-CoV-2 has an enzyme called the main protease, which is essential for ...
Live Science on MSN
A pill can stop people from developing COVID after being exposed to the virus, trial finds
A pill called ensitrelvir is the first drug shown to effectively reduce infection after exposure to SARS-CoV-2.
10don MSN
Antiviral ensitrelvir cuts risk of COVID-19 in household contacts by two-thirds, study finds
The antiviral drug ensitrelvir prevents infection in household contacts of COVID-19 patients when given within 72 hours after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results